Physician profile
Robin Girdhar
NPI 1821301300
$2,533.39
in general payments reported to CMS, 2019-2025
27 companies · $1,557 in 2025
The $1,557 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $73.78 · 2022: $60.57 · 2023: $174 · 2024: $340 · 2025: $1,557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,028 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,028.18 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $433.76 | 2023-2025 | Strensiq |
| Novo Nordisk INC | $345.94 | 2019-2025 | Ozempic, Wegovy |
| Medtronic, INC. | $232.60 | 2023-2025 | Minimed 780g |
| Abbott Laboratories | $203.39 | 2019-2025 | Freestyle Libre 3, Proclaim, Xience Alpine |
| Lilly USA, LLC | $187.73 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Corcept Therapeutics | $166.95 | 2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $134.48 | 2024-2025 | Gvoke Hypopen |
| Mannkind Corporation | $117.04 | 2025 | |
| Amgen INC. | $105.24 | 2025 | Tepezza, Repatha |
| Tandem Diabetes Care, INC. | $95.53 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Insulet Corporation | $77.73 | 2025 | Omnipod |
| Dexcom, INC. | $56.88 | 2022-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.94 | 2023-2025 | Jardiance |
| Beta Bionics, INC. | $42.54 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Neurocrine Biosciences, INC. | $38.89 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $35.59 | 2024-2025 | |
| Radius Health, INC. | $32.09 | 2025 | Tymlos |
| Madrigal Pharmaceuticals | $24.85 | 2025 | Rezdiffra |
| Kestra Medical Technology Services, INC. | $23.55 | 2022 | |
| Sequel Med Tech, LLC | $22.31 | 2025 | Twiist |
| Bayer Healthcare Pharmaceuticals INC. | $21.16 | 2025 | |
| Cequr Corporation | $20.28 | 2025 | Cequr Simplicity |
| Merck Sharp & Dohme LLC | $15.98 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $15.32 | 2020 | |
| Janssen Pharmaceuticals, INC | $13.49 | 2022 | |
| Sanofi-Aventis U.S. LLC | $10.97 | 2020 | |
| Cardiovascular Systems INC. | $6.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Girdhar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.